Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
455.48
-1.88 (-0.41%)
At close: Dec 5, 2025, 4:00 PM EST
455.97
+0.49 (0.11%)
After-hours: Dec 5, 2025, 7:46 PM EST
Vertex Pharmaceuticals Market Cap
Vertex Pharmaceuticals has a market cap or net worth of $115.56 billion as of December 5, 2025. Its market cap has decreased by -3.91% in one year.
Market Cap
115.56B
Enterprise Value
105.39B
1-Year Change
-3.91%
Ranking
Category
Stock Price
$455.48
Market Cap Chart
Since December 1, 1998, Vertex Pharmaceuticals's market cap has increased from $611.50M to $115.56B, an increase of 18,798.42%. That is a compound annual growth rate of 21.40%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 4, 2025 | 116.04B | 11.89% |
| Dec 31, 2024 | 103.71B | -1.09% |
| Dec 29, 2023 | 104.85B | 41.44% |
| Dec 30, 2022 | 74.13B | 32.76% |
| Dec 31, 2021 | 55.83B | -9.15% |
| Dec 31, 2020 | 61.46B | 9.15% |
| Dec 31, 2019 | 56.30B | 32.95% |
| Dec 31, 2018 | 42.35B | 11.74% |
| Dec 29, 2017 | 37.90B | 107.41% |
| Dec 30, 2016 | 18.27B | -40.90% |
| Dec 31, 2015 | 30.92B | 8.21% |
| Dec 31, 2014 | 28.57B | 64.52% |
| Dec 31, 2013 | 17.37B | 91.17% |
| Dec 31, 2012 | 9.09B | 31.16% |
| Dec 30, 2011 | 6.93B | -2.69% |
| Dec 31, 2010 | 7.12B | -8.32% |
| Dec 31, 2009 | 7.76B | 69.85% |
| Dec 31, 2008 | 4.57B | 48.74% |
| Dec 31, 2007 | 3.07B | -34.61% |
| Dec 29, 2006 | 4.70B | 71.34% |
| Dec 30, 2005 | 2.74B | 223.10% |
| Dec 31, 2004 | 848.90M | 5.56% |
| Dec 31, 2003 | 804.20M | -33.56% |
| Dec 31, 2002 | 1.21B | -34.33% |
| Dec 31, 2001 | 1.84B | -56.32% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 904.62B |
| Johnson & Johnson | 486.51B |
| AbbVie | 399.57B |
| UnitedHealth Group | 299.75B |
| AstraZeneca | 280.82B |
| Novartis AG | 255.15B |
| Merck & Co. | 247.51B |
| Abbott Laboratories | 217.50B |